Metrics
The numbers behind Penumbra, Inc.: as-reported financial statements and company metrics for FY2021–FY2025, traced to the source filings, opened with the share-price history those statements have to justify. Every linked figure opens the exact page of the filing it was printed on, with the statement row highlighted. Amounts in US$ thousands unless noted.
Reading notes: All figures in thousands of US dollars, as printed in Penumbra's SEC filings ('in thousands, except share and per share amounts'). Citation filings: FY2025/FY2024/FY2023 columns cite the FY2025 Form 10-K (3-year statements); FY2022/FY2021 income, cash-flow and revenue cite the FY2023 Form 10-K; FY2021 balance sheet cites the FY2021 Form 10-K (the FY2023 10-K balance sheet prints only FY2023/FY2022). Revenue disaggregation uses the company's Thrombectomy / Embolization and Access product cut (available for all of FY2021-FY2025); a Revenue by Geography table (United States / International) is shown alongside. The older Vascular / Neuro cut was retired and is not shown. FY2016-FY2018 long-term figures are from the standardized data feed (SEC XBRL) and are shown without page links; FY2016-FY2018 total revenue is feed cost-of-revenue plus feed gross profit. FY2019-FY2020 long-term figures are cited to the FY2021 Form 10-K.
Share Price — Full Available History — 11 Years
The stock closed at $321.19 on Jul 31, 2026 — up 678% over the window shown (+20.8% a year), trading between $36.50 and $359.40. At that close the stock trades at 71× FY2025 diluted EPS as reported below.
Source: market price feed, weekly closes, sampled from 2,733 source observations, Sep 2015–Jul 2026. Price return only, excludes dividends.
Market capitalization $12.6bn.
Market cap = 39.3M shares outstanding × the Jul 31, 2026 close of $321.19. Market-derived, shown without filing links.
FY2025 at a Glance
Net income (US$ thousands)
Diluted EPS
Source: FY2025 consolidated statements [1] [2]. Click any linked figure to open the filing page with the row highlighted.
Revenue by Product Category
| Revenue by Product Category | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Thrombectomy | 437,775 | 511,137 | 677,343 | 815,475 | 947,918 |
| Embolization and Access | 309,815 | 335,996 | 381,179 | 379,140 | 455,747 |
| Total revenue | 747,590 | 847,133 | 1,058,522 | 1,194,615 | 1,403,665 |
| Total revenue growth, derived | — | +13.3% | +25.0% | +12.9% | +17.5% |
Source: Form 10-K revenue disaggregation footnote (Thrombectomy / Embolization and Access) [3] [4]. Click any linked figure to open the filing page with the row highlighted.
Income Statement
Source: Consolidated Statements of Operations [1] [2]. Click any linked figure to open the filing page with the row highlighted.
Columns marked E are consensus analyst estimates from S&P Capital IQ (CapIQ), shown alongside reported results for direct comparison; they are not company guidance.
Estimate source: S&P Capital IQ (CapIQ) consensus, as of 2026-08-03. Estimate figures are S&P Capital IQ consensus (vendor data — no filing page links). EPS and net income use the normalized (adjusted) consensus where the street reports it. Line-item analyst models (segments, drivers, KPIs) are in the Visible Alpha tab.
Balance Sheet
Source: Consolidated Balance Sheets [5] [6] [7]. Click any linked figure to open the filing page with the row highlighted.
Cash Flow
Source: Consolidated Statements of Cash Flows [8] [9]. Click any linked figure to open the filing page with the row highlighted.
Revenue by Geography
| Revenue by Geography | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| United States | 527,789 | 591,715 | 757,151 | 902,067 | 1,091,761 |
| International | 219,801 | 255,418 | 301,371 | 292,548 | 311,904 |
| Total revenue | 747,590 | 847,133 | 1,058,522 | 1,194,615 | 1,403,665 |
Source: Form 10-K revenue disaggregation footnote (destination of shipment) [3] [4]. Click any linked figure to open the filing page with the row highlighted.
Margins Operating Leverage (% of revenue, as MD A reports)
| Margins Operating Leverage (% of revenue, as MD A reports) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Gross margin % | 63.6% | 63.2% | 64.5% | 63.2% | 67.1% |
| R D as a percentage of revenue | 14.0% | 9.4% | 8.0% | 7.9% | 6.4% |
| SG A as a percentage of revenue | 50.6% | 53.1% | 47.8% | 48.0% | 47.3% |
| Operating margin (income from operations, % of revenue) | (1.0%) | 0.7% | 6.9% | 0.8% | 13.5% |
Source: company filings [10] [11]. Click any linked figure to open the filing page with the row highlighted.
Stock-Based Compensation by Function
| Stock-Based Compensation by Function | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Cost of sales | 2,898 | 3,882 | 5,330 | 4,158 | 3,501 |
| Research and development | 30,037 | 5,908 | 8,838 | 6,868 | 9,749 |
| Sales, general and administrative | 32,828 | 27,588 | 36,348 | 35,138 | 45,963 |
Source: company filings [12] [13]. Click any linked figure to open the filing page with the row highlighted.
Tax, Distribution Channel Workforce
| Tax, Distribution Channel Workforce | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Effective tax rate | 125.0% | 151.4% | (14.2%) | 32.9% | 13.4% |
| Sales to distributors (% of revenue) | 16.6% | 18.7% | 16.7% | 13.2% | 10.0% |
| Employees worldwide | 3,800 | 3,900 | 4,200 | 4,500 | 4,700 |
| Advertising costs | — | — | 1,200 | 1,600 | 3,200 |
Source: company filings [14] [15] [16] [17]. Click any linked figure to open the filing page with the row highlighted.
Long-Term Record
| Fiscal year | Total revenue | Income from operations | Net income | Diluted earnings per share | Operating cash flow |
|---|---|---|---|---|---|
| FY2016 | 263,317 | (1,350) | 14,814 | 0.44 | (12,807) |
| FY2017 | 333,764 | 1,165 | 4,657 | 0.13 | 12,691 |
| FY2018 | 444,938 | (852) | 6,601 | 0.18 | 28,808 |
| FY2019 | 547,405 | 47,508 | 48,458 | 1.34 | 26,652 |
| FY2020 | 560,412 | (38,942) | (15,702) | (0.44) | (33,242) |
| FY2021 | 747,590 | (7,501) | 5,284 | 0.14 | 9,502 |
| FY2022 | 847,133 | 6,082 | (2,002) | (0.05) | (55,661) |
| FY2023 | 1,058,522 | 73,551 | 90,954 | 2.32 | 97,333 |
| FY2024 | 1,194,615 | 9,279 | 14,012 | 0.36 | 168,481 |
| FY2025 | 1,403,665 | 189,249 | 177,687 | 4.52 | 238,663 |
Source: consolidated statements across filings; older years from the standardized feed [8] [1] [9] [2]. Click any linked figure to open the filing page with the row highlighted.
Analyst Consensus
Mean target
Median target
High target
Low target
Street ratings: 2 strong buy, 1 buy, 13 hold. Consensus: Hold.
Estimate source: S&P Capital IQ (CapIQ) consensus, as of 2026-08-03. Estimate figures are S&P Capital IQ consensus (vendor data — no filing page links). EPS and net income use the normalized (adjusted) consensus where the street reports it. Line-item analyst models (segments, drivers, KPIs) are in the Visible Alpha tab.
Traceability
350 of 365 figures on this page (96%) link to the filing page where they are printed — click a linked figure to open the source PDF at that page with the row highlighted. Unlinked figures come from standardized data feeds or pre-filing years.
All figures in thousands of US dollars, as printed in Penumbra's SEC filings ('in thousands, except share and per share amounts').
Citation filings: FY2025/FY2024/FY2023 columns cite the FY2025 Form 10-K (3-year statements); FY2022/FY2021 income, cash-flow and revenue cite the FY2023 Form 10-K; FY2021 balance sheet cites the FY2021 Form 10-K (the FY2023 10-K balance sheet prints only FY2023/FY2022).
Revenue disaggregation uses the company's Thrombectomy / Embolization and Access product cut (available for all of FY2021-FY2025); a Revenue by Geography table (United States / International) is shown alongside. The older Vascular / Neuro cut was retired and is not shown.
FY2016-FY2018 long-term figures are from the standardized data feed (SEC XBRL) and are shown without page links; FY2016-FY2018 total revenue is feed cost-of-revenue plus feed gross profit. FY2019-FY2020 long-term figures are cited to the FY2021 Form 10-K.
Diluted EPS and per-share figures are on net income attributable to Penumbra, Inc.; no stock split occurred over the period, so quarterly EPS is stated on the current share basis (eps_split_adjusted=false).
The FY2024 Impairment charge ($76,945K, a Sixense/immersive-healthcare VR write-down) and negative FY2024 financing (a $100,387K share repurchase) are the two one-time items that depressed FY2024 GAAP operating income and cash flow; Penumbra otherwise carries no debt and had never repurchased stock before FY2024.
Q4 FY2025 quarterly income and balance-sheet figures are taken from the FY2025 earnings press release (Exhibit 99.1) and the FY2025 10-K; the press release prints no cash-flow statement, so Q4 single-quarter cash flows are derived from the FY2025 10-K full-year statement minus the Q3 nine-month year-to-date 10-Q (all derived values reconcile exactly and cross-check the quarterly data feed).
2 figure(s) differed between the data feed and the filing; the filing value is shown (see the run's metrics/metrics_tab.json for the audit trail).